> >

Grant Information

Grant ID	DP220039
Awarded On	August 17, 2022
Title	Single Dose 186RNL for Leptomeningeal Metastases: Multicenter Phase 1/2a Study to Determine MTD/MFD, Safety & Efficacy, Leading to Pivotal Registrational Trial
Program	Product Development Research
Award Mechanism	Texas Company Product Development Awards
Institution/Organization	PLUS Therapeutics, Inc.
Principal Investigator/Program Director	Marc Hedrick
Cancer Sites	Breast, Lung and Bronchus, Skin
Contracted Amount	$17613605
Lay Summary	PLUS Therapeutics’ Rhenium-186 NanoLiposome (186RNL) is a novel radiotherapeutic being developed to combat rare and difficult-to-treat cancers. Currently in clinical development for recurrent glioblastoma, 186RNL is safe and well-tolerated while delivering a radiation dose to the tumor that is up to 15 times higher than typically achievable with standard radiation therapy. PLUS now plans to develop 186RNL to treat leptomeningeal metastases (LM), a rare but typically fatal complication of advanced cancer affecting the fluid-lined structures surrounding the brain and spinal cord. LM affects over 110,000 people in the U.S. every year and, even with the best available care, is rapidly fatal with... Read More PLUS Therapeutics’ Rhenium-186 NanoLiposome (186RNL) is a novel radiotherapeutic being developed to combat rare and difficult-to-treat cancers. Currently in clinical development for recurrent glioblastoma, 186RNL is safe and well-tolerated while delivering a radiation dose to the tumor that is up to 15 times higher than typically achievable with standard radiation therapy. PLUS now plans to develop 186RNL to treat leptomeningeal metastases (LM), a rare but typically fatal complication of advanced cancer affecting the fluid-lined structures surrounding the brain and spinal cord. LM affects over 110,000 people in the U.S. every year and, even with the best available care, is rapidly fatal with a 1-year survival rate of only 7%. To treat LM, 186RNL will circulate throughout the fluid surrounding the brain and spinal cord, targeting the cancer cells with high doses of radiation while minimizing exposure to normal tissues. The goals are to improve the patient’s quality of life and extend their survival. 186RNL is being developed and manufactured in Texas. Support for development of 186RNL fits with CPRIT’s mission to expedite innovation in new product development and to promote cancer research in Texas. Whenever possible, PLUS will utilize Texas-based businesses that conduct clinical research. In line with CPRIT’s priorities, the Award will allow PLUS to continue to provide high paying jobs in Texas and develop a therapy that addresses a very challenging unmet medical need. Read Less